Pharmaceuticals

The granite entrance of the Daniel Patrick Moynihan United States Courthouse at 500 Pearl Street, with its name in gold letters above bronze doors and bollards along the pavement.

The FTC Says Martin Shkreli Traded Shares in at Least 60 Drug Companies Despite a Lifetime Ban. It Wants His Profits, With No Offset for Losses.

The Federal Trade Commission and seven states asked a federal judge in Manhattan on Tuesday 13 October to hold Martin Shkreli in civil contempt of the 2022 order banning him from the pharmaceutical industry for life. They allege he has traded shares in more than 60 drug companies since leaving prison and promoted short positions on livestreams. The court has not ruled, and no response from Shkreli or his lawyers had been reported.

By Daniel Okafor October 13, 2026

Four surgeons in blue gowns, caps and masks, two wearing magnifying headlamps, lean over a patient during an operation in a brightly lit operating room.

The Deal

Viatris Was Built on Generics. It Is Paying $1.65 Billion for Two Pain Drugs That Will Face Them.

Viatris has agreed to buy Pacira BioSciences for $36.50 a share in cash, about 45 per cent above Wednesday's close. It gets two non-opioid pain drugs with about $692 million of sales last year. Generic versions of the larger one, Exparel, are due to start arriving in early 2030 under patent settlements.

By Cory Chamberlain October 9, 2026

A pharmacy technician reaching along a shelf of white medication bottles in a hospital dispensary.

Health

The Drug Shortage Is a Manufacturing Problem Wearing a Pharmacy Uniform

The medicines that run short are almost never the expensive new ones. They are decades-old generics made on thin margins in a handful of plants, where a single inspection failure removes a meaningful share of world supply.

By Thomas Gutierrez August 29, 2026

Pharmaceuticals

Tagged stories

The FTC Says Martin Shkreli Traded Shares in at Least 60 Drug Companies Despite a Lifetime Ban. It Wants His Profits, With No Offset for Losses.

Viatris Was Built on Generics. It Is Paying $1.65 Billion for Two Pain Drugs That Will Face Them.

The Drug Shortage Is a Manufacturing Problem Wearing a Pharmacy Uniform